Two multitargeted agents are being evaluated in a squamous-exclusive NSCLC population: (1) nintedanib, an inhibitor of VEGFR1 through 3, FGFR1 through 4, platelet-derived growth factor receptor (PDGFR) α and β, fms-related tyrosine kinase 3 (FLT-3), and members of the src family 55 and (2) ponatinib, a breakpoint cluster (BCR)–c-abl oncogene 1, nonreceptor tyrosine kinase (ABL) inhibitor (approved in December 2012 for treating two types of leukemia) that has also been shown to inhibit the four FGFRs, fueling research to determine its therapeutic potential as an FGFR inhibitor 57. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.